Short answer
Spyre Therapeutics, Inc. (SYRE) filed its fiscal 2025 10-K annual report with the SEC on Feb 19, 2026. It reported revenue of $0 and net income of −$155M.
- Top risk flagged: Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
FY2025 key financial metrics · XBRL
- Revenue
- $0
- Net income
- −$155M
- +25.4% YoY
- ROE
- -21.7%
- +18.5 pp YoY
- Operating cash flow
- −$169M
- −7.5% YoY
Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) FY2025 10-K on SEC EDGAR. USD.
Spyre Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model redesigned as clinical stage biotech focused on next-generation monoclonal antibodies for IBD and immune-mediated diseases
- Emphasis on half-life extended antibodies aiming for less frequent, self-administered subcutaneous injections
- Planning combination therapy trials to enhance efficacy beyond monotherapies in IBD
- Operational risks from macroeconomic factors including inflation, geopolitical tensions, and supply chain disruptions highlighted with uncertain financial impact
- Early-stage with no selected delivery technology, reflecting ongoing platform development and pipeline innovation
Management Discussion & Analysis
- No profitability or margin data provided due to early-stage operations and recent acquisitions
- Best segment: α4β7 integrin program (SPY001) licensed July 2023 for global therapeutic development
- Capital allocation details not disclosed; emphasis on exercise of license options and exclusive IP rights acquisition
- Forward outlook: advancing multiple research programs with exclusive licenses, ongoing option for final program license
Risk Factors
- Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
- Macroeconomic impact of $2.0M lease termination fee for Austin office abandonment creating liquidity pressure
- Operational risk from reliance on Paragon and multiple CROs/CMOs for R&D services accruing significant expenses
- Competitive risk from inconclusive Phase 1/2 trial results for pegtarviliase triggering strategic alternatives process
- Financial risk from $6.4M restructuring expenses and 83% workforce reduction impacting organizational stability
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.